All In Biotech

Drug Trial Radar · NCT03013517

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut

Last checked: Nov 19, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

300

Actual

Start

Jan 23, 2017

Primary completion

Nov 23, 2019

Study completion Mar 2023

Sponsor

Lead sponsor
DBV TechnologiesIndustry
Sponsor type
Industry
First posted
Jan 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, follow-up study for subjects who completed the PEPITES study. Subjects will be offered enrollment in this follow-up study to receive Viaskin Peanut 250 μg for 2 additional years if previously on active treatment in the PEPITES study, or for 3 years if previously on placebo in the PEPITES study.

Conditions

  • Peanut Allergy

Interventions

  • Viaskin Peanut 250µgDrug

    DBV712 250 µg, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % of subjects originating from the active arm of PEPITES reaching an Eliciting Dose (ED) ≥ 1,000 mg after 24 months of additional treatment in PEOPLETime frame: Month 24

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of California, Rady Children's Hospital

    San Diego, California

  • Stanford University School of Medicine

    Stanford, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • Ann & Robert Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Childrens' Hospital

    Boston, Massachusetts

  • Jaffe Food Allergy Institute

    New York, New York

  • The University of North Carolina - Chapell Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Children's Medical Center of Dallas

    Dallas, Texas

  • Baylor College of Medicine - Texas Children's Hospital

    Houston, Texas

  • ASTHMA, Inc.

    Seattle, Washington

  • Allergy Medical

    Brisbane, Australia

  • Princess Margaret Hospital for Children

    Perth, Australia

  • Children's Hospital Westmead

    Sydney, Australia

  • Centre de Recherche Appliquée en Allergie de Quebec

    Québec, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Cheema Research Inc.

    Mississauga, Ontario, Canada

  • Ottawa Allergy Asthma Research Institute

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research Inc.

    Toronto, Ontario, Canada

  • CHUM & CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • St.-Marien-Hospital

    Bonn, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Clinical Investigations Unit

    Cork, Ireland

  • Our Lady's Children's Hospital

    Dublin, Ireland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.